ARCHIVES

Interim Analysis of Phase III Data Preferable For Accelerated Approval, FDA’s Pazdur Says

This article is from The Cancer Letter archive.

Vol. 28 No. 32 | September 6, 2002

Download PDF Visit The Full Archive

Related Articles

In Brief: NSABP Proposal Selected for Tamoxifen Trials; NIH Building To Be Named After Silvio Conte

March 8, 1991

HEW Ruling Limits Distribution Of Chemicals From Repository To Contractors, Government

May 7, 1976

Zevalin Regimen Effective In Mantle Cell Lymphoma

January 30, 2004

In Brief: Abeloff, Fisher Lead ASCO; Henney Replaces Antman On Govt. Relations; Ultmann Retires

May 31, 1991

Sullivan Accuses Tobacco Industry With “Lies, Blue smoke And Mirrors”

June 15, 1990

Lilly Made False Claims About Ralozifene Reducing Breast Cancer risk, Judge Rules

July 30, 1999